Antifibrotic Effects of Aldosterone Receptor Blocker (Spironolactone) in Patients with Chronic Kidney Disease

dc.contributor.authorGüney, İbrahim
dc.contributor.authorSelçuk, N. Yılmaz
dc.contributor.authorAltıntepe, Lütfullah
dc.contributor.authorAtalay, Hüseyin
dc.contributor.authorBaşarali, M. Kemal
dc.contributor.authorBüyükbaş, Sadık
dc.date.accessioned2020-03-26T17:37:52Z
dc.date.available2020-03-26T17:37:52Z
dc.date.issued2009
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractAims. Proteinuria and transforming growth factor beta (TGF-beta) are parameters that can lead to glomerulosclerosis and tubulointerstitial fibrosis. All components of the renin-angiotensin-aldosterone system (RAAS) activate the TGF-beta. Aldosterone may not be inhibited with angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) due to aldosterone escape. We aimed to evaluate the effect of spironolactone on parameters leading to fibrosis. Methods. This prospective study included 30 non-diabetic chronic kidney disease (CKD) patients treated with ACEIs and/or ARBs. The patients were divided into two groups that are similar in terms of demographic parameters. 25 mg of spironolactone was added to group 1 (n = 15) for six months, though it was not administered to group 2 (n = 15). Creatinine (U-Cr), protein (U-Prot), and TGF-beta 1 (U-TGF-beta 1) were measured in spot urine sample in the beginning of study and six months later. Results. Twenty-four patients completed the study. There were no significant changes in mean blood pressure, glomerular filtration rate, creatinine, albumin, and plasma aldosterone concentrations during the observation period in either group. U-Prot/U-Cr (mg/mg Cr) was reduced from 2.43 +/- 4.85 at baseline to 1.66 +/- 3.51 at sixth month (p = 0.003) in group 1. In addition, U-TGF-beta 1/U-Cr (ng/mg Cr) was also reduced from 22.50 +/- 6.65 at baseline to 17.78 +/- 10.94 at sixth month (p = 0.041) in the same group. U-TGF-beta 1/U-Cr and U-Prot/U-Cr ratios after the sixth month were not found significant compared with baseline values in group 2. Conclusion. Spironolactone reduced both proteinuria and urinary TGF-beta 1 excretion in CKD patients. We consider that spironolactone would be beneficial to prevent progression of renal fibrosis in CKD.en_US
dc.description.sponsorshipAli Raif Drug Industry A.C.en_US
dc.description.sponsorshipThis study was supported by Ali Raif Drug Industry A.C. for providing TGF-beta 1 and aldosterone kits.en_US
dc.identifier.doi10.3109/08860220903150312en_US
dc.identifier.endpage784en_US
dc.identifier.issn0886-022Xen_US
dc.identifier.issn1525-6049en_US
dc.identifier.issue9en_US
dc.identifier.pmid19925284en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage779en_US
dc.identifier.urihttps://dx.doi.org/10.3109/08860220903150312
dc.identifier.urihttps://hdl.handle.net/20.500.12395/23284
dc.identifier.volume31en_US
dc.identifier.wosWOS:000273987900002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.relation.ispartofRENAL FAILUREen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectTGF-beta 1en_US
dc.subjectchronic kidney diseaseen_US
dc.subjectspironolactoneen_US
dc.subjectproteinuriaen_US
dc.titleAntifibrotic Effects of Aldosterone Receptor Blocker (Spironolactone) in Patients with Chronic Kidney Diseaseen_US
dc.typeArticleen_US

Dosyalar